Please assess the completion status of the following clinical trial:

Trial Title: A Pharmacokinetic, Tolerability and Safety Study of Icatibant in Children and Adolescents With Hereditary Angioedema

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Two through \<18 years of age at the time of first HAE attack.~   * Prepubertal and pubertal/postpubertal subjects experiencing and acute cutaneous, abdominal, or laryngeal HAE attack treated with icatibant as part of this study.~  * Pubertal/postpubertal subjects with HAE who are treated with icatibant, but not during an attack.~2. Documented diagnosis of HAE Type I or II.~3. Informed consent (and subject assent as appropriate) signed by the subject's parent(s)or legal guardian(s).~Exclusion Criteria:~1. Diagnosis of angioedema other than HAE.~2. Participation in another clinical trial that involves the use of any investigational product (drug or device)within 30 days prior to study enrollment or at any time during the study.~3. Any known factor/disease that might interfere with the treatment compliance, study conduct,or result interpretation.~4. Congenital or acquired cardiac anomalies that interfere significantly with cardiac function.~5. Treatment with ACE inhibitors within 7 days prior to treatment.~6. Use of hormonal contraception within the 90 days prior to treatment.~7. Androgen use (eg, stanozolol, danazol, oxandrolone, methyltestosterone, testosterone) within the 90 days prior to treatment.~8. Pregnancy or breastfeeding.~9. A physical condition that interferes with pubertal status determination.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Icatibant (Type: EXPERIMENTAL): Single dose of icatibant 0.4 mg/kg subcutaneous(SC) up to a maximal dose of 30 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).